TransIT®-mRNA Transfection Kit

A high efficiency, low toxicity transfection reagent for large RNA and CRISPR guide RNA

  Product No. Quantity Price Add to Cart
TransIT®-mRNA Transfection Kit
  MIR 2225 0.4 ml $354.00
  MIR 2250 1 ml $634.00
  MIR 2255 5 x 1 ml $2,778.00
  MIR 2256 10 x 1 ml $5,140.00

Product Overview

TransIT®-mRNA (1:1:1)
RNAiMAX (4:1)
Stemfect™ (2:1)
TransIT-mRNA day 1 TransIT-mRNA day 5 TransIT-mRNA day 9 TransIT-mRNA day 14 TransIT-mRNA day 14 cells
RNAiMax day 1 RNAiMax day 5 RNAiMax day 9 RNAiMax day 14 RNAiMax day 14 cells
Stemfect day 1 Stemfect day 5 Stemfect day 9 Stemfect day 14 Stemfect day 14 cells
Click on the red days to view images

Each Kit is supplied with the TransIT®-mRNA Transfection Reagent and the mRNA Boost Reagent

  • Low Cellular Toxicity – Maintain cell density and reduce experimental biases
  • High Efficiency Delivery – Achieve RNA delivery in a large population of cells to ensure experimental success
  • Serum Compatible – Perform transfections in the presence of serum which eliminates the need for a media change and maintains cellular health
  • Deliver Various Sizes of RNA – Ideal for specialized applications, such as virus production, protein expression and CRISPR genome editing

Figures and Data

Delivery of Cas9 mRNA and CRISPR Guide RNA with TransIT-mRNA Transfection Kit

Efficient Genome Editing with Cas9 mRNA + Guide RNA Oligonucleotides. HEK293T/17, U2OS and NHDF cells were co-transfected with 0.5 µg of Cas9 encoding mRNA, 5meC, ψ (Trilink Biotechnologies) and 25nM of PPIB targeting 2-part gRNA (Dharmacon) using TransIT®-mRNA Transfection Kit (0.5 µl/well of 24-well plate of both mRNA Reagent and Boost, Mirus Bio). A T7E1 mismatch detection assay was used to measure cleavage efficiency at 48 hours post-transfection.

High Efficiency and Low Toxicity Transfection Following 14 Consecutive Transfections with TransIT-mRNA Transfection Kit

High Efficiency and Low Toxicity Transfection Following 14 Consecutive Transfections with TransIT®-mRNA Transfection Kit. Repeated daily transfections were performed in the same population of BJ fibroblasts using TransIT®-mRNA Transfection Kit, Lipofectamine® RNAiMAX (Life Technologies) and Stemfect™ RNA Transfection Kit (Stemgent) - with a capped and polyadenylated EGFP mRNA incorporating pseudouridine and 5mC modified bases (Trilink Biotechnologies, Inc.). Multiple reagent-to-RNA ratios were tested and the optimal ratio is represented. Transfections were performed in 12-well plates using the indicated reagent-to-RNA ratios to deliver 1 µg of RNA. GFP and phase contrast images were taken in the same field of view everyday after transfection. Transfection efficiency was measured by flow cytometry on a Guava® easyCyte™ 5HT following 14 consecutive daily transfections (blue bars). Cell viability was determined using cell counts measured during flow cytometry (black line grey bars). Error bars represent the standard deviation of triplicate wells.

TransIT-mRNA Transfection Kit Transfects GFP mRNA into DC 2.4 Dendritic Cells

TransIT®-mRNA Transfection Kit Transfects GFP mRNA into DC 2.4 Dendritic Cells. Using TransIT®-mRNA Transfection Kit, DC 2.4 cells were transfected with (A) 0.5 µg, (B) 1 µg and (C) 2.5 µg of capped and polyadenylated mRNA encoding GFP with 1 µl TransIT®-mRNA Reagent and 1 µl Boost. Cells were seeded overnight at 100,000 cells/well in 24-well plates. Images were taken 10 hours post-transfection.

Data courtesy of Kyle Phua (Principal Investigator: Kam W. Leong), Duke University

Product Resources


Storage Conditions:
All Configurations: Store at 4°C

Product Guarantee:
All Configurations: 1 year

Technical Product Literature

Additional Resources

COA Lookup

Download Certificates of Analysis

COO Lookup

Download Certificate of Origin


Customer Testimonial

"Our lab recently used the TransIT®-mRNA Transfection Kit to show that intracellular delivery of HPLC-purified and pseudouridine-containing mRNA can translate very efficiently without immune activation which is ideal for mRNA-based gene therapy applications. TransIT®-mRNA further facilitated this work through low toxicity transfections of HEK 293T, human dendritic cells (DCs) and primary keratinocytes (Karikó et al. Nucleic Acids Research, 39:e142, 2011)."

Dr. Katalin Kariko

University of Pennsylvania - Department of Neurosurgery

Watch Us On YouTube